L'intérêt à découvert pour Humana donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Humana. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Humana (NYSE:HUM) Stock, Rapport sur les intérêts à découvert

Humana

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Humana Inc

Humanscape

Humacyte Inc

Humble & Fume Inc

Hua Medicine

Humm Group Ltd

Humble Energy Inc

Hummingbird Resources PLC

Humatech Inc

Elevance Health Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) on Tuesday reported first-quarter 2025 revenues of $48.77 billion, up 15% year-over-year, higher than the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $46.29 billion</a>.&nbsp;
The increase was driven by higher premium yields in the Health Benefits segment, acquisitions completed in the past year, Medicare Advantage and Individual ACA membership growth, and CarelonRx product revenue, partially offset by membership <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44917011/elevance-health-reports-first-quarter-2025-results" rel="noreferrer noopener">attrition in Medicaid business</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44675802/health-insurers-surge-after-medicare-agency-increases-payment-rates" rel="noreferrer noopener">Health Insurers Surge After Medicare Agency Increases Payment Rates</a>
The benefit expense ratio was 86.4%, an increase of 80 basis points year over year, reflecting a higher Medicaid medical cost trend, partially offset by out-of-period premium taxes. Reuters noted that the analysts&#8217; average estimate was 86.8%.
&#8220;&#8230;In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces cost&#8230;&#8221; said Gail Boudreaux, President and Chief Executive Officer
Last week, CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>),&nbsp;Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and Elevance Health stocks fell as investors were spooked after UnitedHealth Group, Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) disappointing Q1 earnings and <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44860240/unitedhealth-slashes-2025-outlook-on-medicare-funding-reductions-stock-crashes" rel="noreferrer noopener">slashed 2025 guidance</a>.
The operating expense ratio was 10.9%, improving 70 basis points from the prior year. The adjusted operating expense ratio was 10.7%, an improvement of 60 basis points, primarily driven by expense leverage associated with growth in operating revenue and ongoing cost management, partially offset by out of period premium tax expense during the quarter.
Premiums rose 14.5% to $40.89 billion, product revenue rose 29.1% to $5.81 billion, and services fees fell marginally to $2.07 billion.
Adjusted earnings per share reached $11.97, up 10.8%, beating the consensus of $11.38.
The operating revenue of the health benefits segment was $41.4 billion in the first quarter of 2025, an 11% increase driven primarily by higher premium yields and growth in our Medicare Advantage and Individual ACA plan membership.
Medical membership totaled approximately 45.8 million as of March 31, 2025, an increase of 99 thousand from year-end 2024, driven by growth in Medicare Advantage and Commercial risk-based member, partially offset by a decline in Commercial fee-based membership from a known customer transition.
Operating revenue for Carelon was $16.7 billion, up 38%, driven by recent acquisitions in home health and pharmacy services, growth in CarelonRx product revenue, and the scaling of innovative risk-based capabilities in Carelon Services.
Guidance: Elevance Health reaffirms the 2025 adjusted EPS outlook of $34.15-$34.85 versus consensus of $34.22.
Price Action: ELV stock is up 1.87% at $414.31 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44907170/upcoming-pfizer-earnings-call-might-be-focused-on-tariffs-policy-risks-and-obesity-pipeline" target="_blank" rel="noreferrer noopener">Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline</a></li>
</ul>
Photo via Shutterstock

Earnings

Large Cap

News

Guidance

Health Care

Movers

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Despite Medicaid Pressure, Elevance Health Delivers Strong Q1 Performance, Reiterates Profit Outlook

Stocks in the U.S. were trading sharply lower by midday Monday, while gold and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surged in tandem, as a renewed political storm surrounding Federal Reserve independence shook confidence in the U.S. dollar and triggered a broad-based risk-off <a href="https://www.benzinga.com/government/regulations/25/04/44899280/are-investors-selling-us-treasuries-as-trump-attacks-powell-heres-what-latest-etf-flows-tell-you">mood on U.S. assets.</a>
The market opened the post-Easter trading week with deep losses, after President Donald Trump took to Truth Social demanding immediate rate cuts and blasting Fed Chair Jerome Powell as "Mr. Too Late," accusing him of past political bias and inflation misjudgment. 
Trump wrote that there's "virtually no inflation" and warned of an economic slowdown unless Powell acts "NOW."
The latest barrage reignited fears that central bank independence may be under direct threat, just days after reports emerged that the Trump administration is weighing Powell's removal ahead of his scheduled 2026 term expiration.
The U.S. Dollar Index (DXY) fell as much as 1%, marking its lowest level since early 2022, as the greenback weakened against a basket of major currencies including the Japanese yen, euro and Swiss franc. 
The selloff has intensified speculation that foreign investors may accelerate the repatriation of capital from U.S. assets amid mounting political and monetary instability.
The S&amp;P 500 dropped 2.8% by midday, with the Nasdaq 100 falling 3%, led lower by steep losses in megacap tech and financials. Every major sector was in the red, with 490 of the 500 S&amp;P 500 stocks trading lower.
In another break from historical norms, U.S. Treasury yields climbed even as equities tanked and volatility spiked. The 30-year yield rose 7 basis points to 4.87%, signaling investor selling of government debt. The CBOE Volatility Index (VIX) jumped 15%. 
Gold-linked equities were the few bright spots in an otherwise brutal session. Gold prices – as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) – surged 2.6% to $3,410 per ounce, pushing the year-to-date gain to nearly 30%—on track for the metal's best annual performance since 2007. 
The move extends gold's stunning 2-month rally, now nearing 20%, amid persistent demand for safe-haven assets.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) gained 3.5% to trade at $88,274, echoing gold's momentum as investors seek alternatives to fiat currencies.
Monday&#8217;s Performance In Major US Indices, ETFs
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg (%)</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,837.81</td>
<td>-2.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>38,097.81</td>
<td>-2.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,135.83</td>
<td>-2.8%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>17,727.70</td>
<td colspan="2">-3.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:20 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 2.8% up to $511.49.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 2.7% to $380.65.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;tumbled 3% to $430.76.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 2.3% to $182.28.</li>
<li>The&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) outperformed, yet falling 1.4%; the&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 3.5%.</li>
</ul>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top Performers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company Name</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>)</td>
<td>3.81%</td>
</tr>
<tr>
<td>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>)</td>
<td>2.89%</td>
</tr>
<tr>
<td>Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</td>
<td>1.75%</td>
</tr>
<tr>
<td>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>1.02%</td>
</tr>
<tr>
<td>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)</td>
<td>0.86%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst Performers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company Name</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Universal Health Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)</td>
<td>-10.31%</td>
</tr>
<tr>
<td>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>)</td>
<td>-8.34%</td>
</tr>
<tr>
<td>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</td>
<td>-8.23%</td>
</tr>
<tr>
<td>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)</td>
<td>-7.48%</td>
</tr>
<tr>
<td>Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</td>
<td>-7.42%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44886209/if-you-had-bet-on-gold-after-the-1971-nixon-shock-youd-have-beaten-the-sp-500-unless-you-did-this-one-thing">If You Had Bet On Gold After The 1971 Nixon Shock, You&#8217;d Have Beaten The S&amp;P 500 — Unless You Did This One Thing</a></li>
</ul>
Photo: FOTOGRIN/Shutterstock

Government

Regulations

Broad U.S. Equity ETFs

Econ #s

Federal Reserve

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

MRNA

NFLX

ULTA

Select Sector SPDR-Consumer Discretionary

Wall Street Sinks, Dollar Slides As Trump Ramps Up Fed Attacks: What's Driving Markets Monday?

WIIM

ALHC

Shares of health insurance stocks are trading lower in sympathy with UnitedHealth, which reported worse-than-expected Q1 results and cut its FY25 adjusted EPS guidance below estimates on Thursday.

These large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) stock dipped 23.60% after the company reported worse-than-expected first-quarter results and cut its FY25 adjusted <a href="https://www.benzinga.com//node/44860240" target="_blank" rel="noreferrer noopener">EPS guidance below estimates</a>.</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) shares declined 16.55% after the company announced it had bought a <a href="https://www.benzinga.com//node/44862867" target="_blank" rel="noreferrer noopener">stake in Worldpay for $6.6 billion</a>.</li>
<li>Applovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) stock decreased 9.71% after Goldman Sachs analyst Eric Sheridan cut its price <a href="https://www.benzinga.com/quote/app/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast from $500 to $335</a>.</li>
<li>Humana Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) stock was down 8.88% on pin action after UnitedHealth Group, Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reported worse-than-expected <a href="https://www.benzinga.com//node/44860240" target="_blank" rel="noreferrer noopener">first-quarter results</a>.</li>
<li>DaVita Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) shares fell 8.69% in the last week.</li>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) stock declined 8.20% amid <a href="https://www.benzinga.com//node/44821791" target="_blank" rel="noreferrer noopener">the FTC&#8217;s antitrust trial</a>. Several analysts lowered the <a href="https://www.benzinga.com/quote/meta/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) shares dived 7.70%.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) stock was down 7.37%.</li>
<li>Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) shares fell 6.97% amid overall market weakness after Fed Chair Powell made remarks at the Economic Club.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares declined 6.46% after JP Morgan analyst Samik Chatterjee cut its price forecast on the <a href="https://www.benzinga.com/quote/smci/analyst-ratings" target="_blank" rel="noreferrer noopener">stock from $45 to $39</a>.</li>
<li>GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) shares declined 6.24% after NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) said the US government recently informed that it would need a <a href="https://www.benzinga.com//node/44856114" target="_blank" rel="noreferrer noopener">license to export chips to China</a>.</li>
</ol>
Photo via Shutterstock

Equities

BURL

CRWV

NVDA

RDDT

SMCI

YUMC

These Large Cap Tech And Healthcare Stocks Had A Poor Run In Easter Week (Apr 14-Apr 18): Are These In Your Portfolio?

Three <a href="https://www.benzinga.com/etfs">healthcare-themed ETFs</a> were in sharp spotlight Thursday as the sector got through a wild trading day, fueled by UnitedHealth&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) earnings disappointment and steep stock decline. While insurers weighed down on broad healthcare gauges, a drugmakers rally, led by Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), limited the damage.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;</a>
ETFs In Spotlight
Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)
<ol>
<li></li>
</ol>
1-Day Return (Thursday): -0.6%
Top holdings of this fund are Eli Lilly, UnitedHealth, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>). UnitedHealth dropped 2.4%, spooking XLV early in the session. The ETF trimmed losses, however, as Eli Lilly rallied 14.3% on <a href="https://www.benzinga.com/general/biotech/25/04/44878381/eli-lilly-rallies-over-14-notches-best-day-since-june-2000-on-oral-weight-loss-drug-results-analysts-react">good weight-loss pill trial news</a>, calling out the group&#8217;s internal divergency. Barring Thursday&#8217;s turmoil, though, XLV is off just 1.5% for the year so far and commands a 17x forward-earnings multiple—below its five-year history and the large-cap S&amp;P 500&#8217;s 20x multiple, according to Barron&#8217;s.
iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)
<ol start="2">
<li></li>
</ol>
1-Day Performance: +4.6%
IHE surged as investors rotated into large-cap pharma stocks, bolstered by Eli Lilly's rally. The gains came despite a nearly 8% drop in Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Lilly's rival in the GLP-1 space.
SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)
<ol start="3">
<li></li>
</ol>
1-Day Performance: +2.15%
XPH tracked gains across a broader basket of pharmaceutical names, benefiting from bullish sentiment on drugmakers following Lilly's breakthrough.
Market Context: A Sector Of Contrasts
UnitedHealth&#8217;s <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">poor earnings and soft guidance</a> spooked healthcare investors, highlighting how exposed insurers are to firm-specific disappointments and policy-level risks. The 22% decline in the stock not only heavily burdened XLV—where it is the second-largest position—but pulled down peers CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) too.
However, the overall message of the day was one of subtlety and not panic. Eli Lilly&#8217;s explosion proved the influence of innovation in developing market-driving catalysts within the health-care sector. It provided the stimulus that helped neutralize weakness within managed care and indicated how investors in ETFs are able to still uncover segments of strength despite sector-wide selloffs.
At the same time, Johnson &amp; Johnson kept its steady pace going with the help of strong earnings.
Device and medical equipment manufacturers like Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), Zimmer Biomet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), and Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) are also attracting investor attention as Wall Street is wagering on secular demand from the aging population.
Takeaway
The health care industry remains far from monolithic. Thursday&#8217;s ETF action underscored the increasing divide between pressured insurers and pharma names benefiting from innovation tailwinds. For investors in ETFs, the message is simple: thematic selectivity is key. Though political headlines and earnings fluctuations might continue to shock portions of the industry, solid fundamentals within pharma and medtech imply there&#8217;s still ample healthy opportunity to go around.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44876466/the-10k-handbag-hoax-tiktoks-trade-war-puts-luxury-etfs-in-the-hot-seat">The $10K Handbag Hoax? TikTok&#8217;s Trade War Puts Luxury ETFs In The Hot Seat</a></li>
</ul>
Image: Shutterstock/The Image Party

Sector ETFs

iShares Dow Jones US Pharmaceuticals Index Fund

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot

CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) and Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) shares are moving lower on Thursday after UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reported earnings prior to <a href="https://www.benzinga.com//node/44860240">the market opening.</a>
What To Know: UnitedHealth reported worse-than-expected earnings today, reporting adjusted earnings per share of $7.20, missing analysts&#8217; expectations of $7.29. In addition, the insurance giant posted sales of $109.58 billion, missing analysts&#8217; expectations of $111.60 billion.
The company also cut its guidance for fiscal-year 2025 adjusted earnings per share. It now expects adjusted earnings per share of $26 to $26.50, versus analysts&#8217; estimate of $29.73. The company had previously expected adjusted earnings per share of $29.50 to $30.
UnitedHealth said the guidance change reflects higher care activity in its Medicare Advantage business and unexpected changes in Optum Health member profiles due to low engagement from beneficiaries in plans exiting certain markets.
Shares of CVS, Humana, Elevance and other health insurance companies may be trading lower after UnitedHealth reported earnings, as investors assess the health insurance industry as a whole. For instance, if UnitedHealth, the largest insurer, is missing analysts&#8217; expectations, investors may believe other companies are also facing similar challenges. The lowered guidance could also signal that UnitedHealth is feeling sustained pressure, which may weigh on the broader sector.
Related Link: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44863580/bitcoin-stuck-below-85000-bull-run-shakeout-or-bearish-downtrend">Bitcoin Stuck Below $85,000: Bull Run Shakeout Or Bearish Downtrend?</a>
Price Action: At the time of writing, CVS stock is trading 3.16% lower at $64.29, Humana stock is moving 7.80% lower at $260.04 and Elevance shares are trading 3.06% lower at $422.02, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: Courtesy of CVS Health Corporation

CVS, Humana and Elevance Shares Are Trading Lower Thursday: What's Going On?

Shares of health insurance stocks are trading lower in sympathy with UnitedHealth, which reported worse-than-expected Q1 results and cut its FY25 adjusted EPS guidance below estimates.

Baird analyst Michael Ha maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and raises the price target from $270 to $300.

Price Target

Analyst Ratings

Baird Maintains Neutral on Humana, Raises Price Target to $300

Wall Street pared early morning gains by midday Monday, as investor caution returned despite a temporary easing in U.S.-China trade tensions. While the initial market reaction was positive, especially in tech, enthusiasm faded as <a href="https://www.benzinga.com/markets">the trading session progressed.</a>
Over the weekend, the White House announced a provisional exemption for smartphones and semiconductors from China&#8217;s proposed 145% trade tariff. These items will instead face a 20% levy—linked to fentanyl-related enforcement—until sector-specific duties are finalized.
The development triggered a strong premarket rally in technology stocks. Yet, those gains were sharply trimmed by midday amid broader geopolitical and policy concerns.
During a White House meeting with El Salvador President Nayib Bukele, President Donald Trump said he plans to impose tariffs on pharmaceutical imports to boost domestic manufacturing. 
He reiterated a hardline stance on Iran, warning of severe consequences if Tehran develops nuclear weapons, but also suggested &#8220;flexibility&#8221; in tariff negotiations, emphasizing a desire not to harm U.S. businesses.
Defensive and domestic-oriented sectors such as real estate, utilities, and consumer staples outperformed broader markets. In contrast, consumer discretionary was the only sector trading in negative territory.
Treasury yields dropped significantly, reflecting increased demand for U.S. government debt and easing fears of foreign liquidation. The 2-year yield fell 10 basis points to 3.87%, while 10-year benchmark yield dropped 7 basis points to 4.42%.
Gold pulled back 1% to $3,200 per ounce, pausing after a three-session rally. Crude oil fell 0.8% to $61 per barrel, while natural gas slid 2.9% to $3.39 per MMBtu, eyeing its lowest level since last Wednesday.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was little changed at $84,000, while Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) gained 2.1% to $1,630.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,326.49</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,377.08</td>
<td>0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,695.41</td>
<td>0.0%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,856.16</td>
<td colspan="2">-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.5% up to $537.23.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.4% to $403.81.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.4% higher to $454.38.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.1% higher to 184.74.</li>
<li>The&nbsp;Real Estate&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 1.9%; the&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 0.5%.</li>
</ul>
In company news, Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) reported stronger-than-expected earnings during the first quarter, and shares rose 1.9%.
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company </th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>)</td>
<td>6.91%</td>
</tr>
<tr>
<td>Charles River Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)</td>
<td>5.98%</td>
</tr>
<tr>
<td>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)</td>
<td>4.69%</td>
</tr>
<tr>
<td>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)</td>
<td>4.64%</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>4.15%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)</td>
<td>-3.80%</td>
</tr>
<tr>
<td>DaVita Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>)</td>
<td>-3.61%</td>
</tr>
<tr>
<td>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-3.04%</td>
</tr>
<tr>
<td>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>)</td>
<td>-2.39%</td>
</tr>
<tr>
<td>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>-2.36%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/44794083/7-chipmaker-stocks-set-to-gain-as-trump-delays-tariff-blow-on-key-china-tech-imports-bank-of-america">7 Chipmaker Stocks Set To Gain As Trump Delays Tariff Blow On Key China Tech Imports: Bank Of America</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Economics

Tech

$ETH

AMZN

ENPH

FSLR

PLTR

SNDK

XLRE

Wall Street Pulls Back After Early Gains As Tariff Uncertainties Persist: What's Driving Markets Monday?

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and raises the price target from $270 to $322.

Barclays Maintains Equal-Weight on Humana, Raises Price Target to $322

Truist Securities analyst David Macdonald maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and raises the price target from $290 to $325.

Truist Securities Maintains Hold on Humana, Raises Price Target to $325

Investors with a lot of money to spend have taken a bullish stance on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HUM, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for Humana.
This isn't normal.
The overall sentiment of these big-money traders is split between 45% bullish and 27%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $59,520, and 10, calls, for a total amount of $1,440,080.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $245.0 to $340.0 for Humana during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Humana stands at 637.88, with a total volume reaching 1,421.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Humana, situated within the strike price corridor from $245.0 to $340.0, throughout the last 30 days.
<h3>Humana Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744300826_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.5</td>
<td>$18.8</td>
<td>$20.5</td>
<td>$280.00</td>
<td>$397.7K</td>
<td>3.3K</td>
<td align="right">190</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.5</td>
<td>$18.8</td>
<td>$20.5</td>
<td>$280.00</td>
<td>$373.1K</td>
<td>3.3K</td>
<td align="right">738</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.5</td>
<td>$18.8</td>
<td>$20.5</td>
<td>$280.00</td>
<td>$334.1K</td>
<td>3.3K</td>
<td align="right">190</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/11/25</td>
<td>$45.5</td>
<td>$39.6</td>
<td>$41.91</td>
<td>$245.00</td>
<td>$83.8K</td>
<td>30</td>
<td align="right">0</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$15.8</td>
<td>$13.3</td>
<td>$13.3</td>
<td>$280.00</td>
<td>$66.5K</td>
<td>1.5K</td>
<td align="right">453</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Humana's Current Market Status</h3>
<ul>
<li>With a volume of 528,338, the price of HUM is down -0.22% at $284.9. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 20 days.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $321.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Guggenheim downgraded its action to Buy with a price target of $326. 
&#x2A; An analyst from Mizuho persists with their Outperform rating on Humana, maintaining a target price of $316. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Humana options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

Humana Options Trading: A Deep Dive into Market Sentiment

Guggenheim analyst Jason Cassorla initiates coverage on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Buy rating and announces Price Target of $326.

Initiation

Guggenheim Initiates Coverage On Humana with Buy Rating, Announces Price Target of $326

8 analysts have expressed a variety of opinions on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Humana, presenting an average target of $280.38, a high estimate of $316.00, and a low estimate of $255.00. This upward trend is evident, with the current average reflecting a 1.31% increase from the previous average price target of $276.75.
<img src="https://www.benzinga.com/files/images/story/2025/1744203611_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $316.00&#x7C;$305.00 &#x7C; 
&#x7C;Lisa Gill &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $256.00&#x7C;$257.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $270.00&#x7C;$255.00 &#x7C; 
&#x7C;Ben Hendrix &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $283.00&#x7C;$283.00 &#x7C; 
&#x7C;Sarah James &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Neutral &#x7C; $290.00&#x7C;$290.00 &#x7C; 
&#x7C;Erin Wright &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $285.00&#x7C;$301.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $255.00&#x7C;$253.00 &#x7C; 
&#x7C;Jessica Tassan &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $288.00&#x7C;$270.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Humana. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Humana's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Humana's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Humana analyst ratings.</a>
<h2>Delving into Humana's Background</h2>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Key Indicators: Humana's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Humana showcased positive performance, achieving a revenue growth rate of 10.4% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Humana's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2.37%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Humana's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -4.08%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Humana's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.44%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Humana's debt-to-equity ratio is below the industry average. With a ratio of 0.72, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 8 Analyst Ratings Have To Say About Humana

Mizuho analyst Ann Hynes maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Outperform and raises the price target from $305 to $316.

Mizuho Maintains Outperform on Humana, Raises Price Target to $316

U.S. stocks staged a broad-based rally on Monday, snapping a volatile losing streak after President Donald Trump hinted at a more diplomatic <a href="https://www.benzinga.com/topic/tariffs">approach to tariff negotiations.</a>
In a post on Truth Social, Trump said the U.S. is handling a "massive amount of requests for negotiations," referencing active talks with South Korea and hinting that China "wants to make a deal, badly."
He also mentioned a joint venture involving an Alaska pipeline and military cost-sharing, asserting that South Korea&#8217;s top negotiation team was en route to the U.S.
Meanwhile, Fed speakers begin to highlight the negative economic impact from tariffs. &#8220;We can&#8217;t really wait to the end of the quarter plus one month before we find out that investment really dropped off and GDP growth is shrinking,&#8221; Chicago Fed President Austan Goolsbee said.
By midday trading in New York, all major U.S. stock indices were firmly in the green. The S&amp;P 500 rose 1.4%, the Dow Jones Industrial Average gained 1.1%, and the tech-heavy Nasdaq Composite led with a 1.8% jump. Technology stocks were the day's clear outperformers, driven by a strong rebound in the semiconductor sector.
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) surged 3.3%, marking its strongest intraday gain since September 2024. Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) led the charge with a 7.3% jump, followed by Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), which both climbed 6.1%.
In commodities, gold prices rose 0.5% to $2,335 per ounce, poised to snap a three-session losing streak. Oil prices also saw a firm recovery, with WTI crude advancing 1.5% to $61.50 per barrel, reversing recent weakness. U.S. Treasury yields remained largely flat. 
In contrast, cryptocurrency markets failed to participate in the rally. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell another 1% to $78,000. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>17,781.63</td>
<td>2.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>38,718.65</td>
<td>2.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,144.86</td>
<td>1.6%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,821.21</td>
<td>0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:20 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.8% to $513.37.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rallied 2% to $387.02.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 1.9% to $431.23.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.4% higher to 180.33.</li>
<li>The&nbsp;Financials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) outperformed, up 2.5%; the&nbsp;Materials&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 0.1%.</li>
</ul>
<h1 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Performers</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Chg %</td>
</tr>
<tr>
<td>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)</td>
<td>9.93%</td>
</tr>
<tr>
<td>Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>)</td>
<td>8.15%</td>
</tr>
<tr>
<td>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>6.48%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) </td>
<td>5.98%</td>
</tr>
<tr>
<td>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</td>
<td>5.77%</td>
</tr>
</tbody>
</table>
</figure>
<h1 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Chg %</td>
</tr>
<tr>
<td>Albemarle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>-8.18%</td>
</tr>
<tr>
<td>lululemon athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>)</td>
<td>-4.53%</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>-4.39%</td>
</tr>
<tr>
<td>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>)</td>
<td>-3.97%</td>
</tr>
<tr>
<td>Ralph Lauren Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>)</td>
<td>-3.50%</td>
</tr>
</tbody>
</table>
</figure>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44696476/ups-expands-delivery-options-with-two-new-ground-services">UPS Expands Delivery Options With Two New Ground Services</a></li>
</ul>
Photo: Shutterstock

AVGO

LULU

MRVL

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Stocks Rebound, Chipmakers Soar On Trade Deal Hopes, Bitcoin Lags: What's Driving Markets Tuesday?

U.S. stocks were higher, with the Dow Jones index surging over 1,300 points on Tuesday.
Shares of Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) rose sharply during Tuesday's session after Infineon Technologies agreed to acquire its Automotive Ethernet <a href="https://in.benzinga.com/25/04/44683383/marvell-plays-ai-hardball-divestiture-sparks-155-upside-says-analyst">Business for $2.5 billion in cash</a>.
The transaction includes Marvell&#8217;s Brightlane Automotive Ethernet portfolio and related assets. The company projected this segment to generate $225 million to $250 million in revenue in 2025, with a gross margin of around 60%.
Marvell Technology shares jumped 10.1% to $56.16 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares jumped 31.8% to $5.60.</li>
<li>NextDecade Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>) gained 23.3% to $7.38 after the company announced a 20-year LNG sale and purchase agreement to supply 1.2 million tonnes per year to a subsidiary of Saudi Aramco.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) gained 21.4% to $8.50.</li>
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares rose 21.1% to $7.36 after the company issued first-quarter preliminary revenue guidance above estimates.</li>
<li>Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) gained 16.1% to $26.60 after HC Wainwright &amp; Co. raised its price target on the stock from $48 to $65 and maintained a Buy rating.</li>
<li>Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) jumped 14.9% to $20.48.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) gained 14.7% to $3.9098.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) climbed 14.6% to $192.29.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) rose 14% to $12.81.</li>
<li>ECARX Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) gained 14% to $1.14 after the company announced it increased its share repurchase program by $20 million to $40 million.</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) rose 12.3% to $286.14 following a WSJ report indicating the Trump administration will increase Medicare Advantage rates.</li>
<li>Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) gained 12.4% to $61.76. Canaccord Genuity analyst Whitney Ijem maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $81 to $92.</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) rose 12.4% to $3.9150.</li>
<li>Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) gained 12.4% to $35.40.</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) rose 10% to $34.26.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) gained 10% to $255.36.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) rose 8.5% to $69.29 after the company announced changes to management and Medicare increased advantage payment rates.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained 7.9% to $105.39.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) rose 7.8% to $85.05.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 6.3% to $248.09.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose 4.2% to $189.13. U.S. consumers are reportedly rushing to Apple stores to purchase new iPhones ahead of potential price hikes caused by President Donald Trump&#8217;s newly announced tariffs on Chinese imports.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44682968/how-to-earn-500-a-month-from-delta-air-lines-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Delta Air Lines Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Trading Ideas

AAOI

AAPL

CRMD

CVNA

GRAB

PCRX

RYTM

SHOP

TSLA

UXIN

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday

Shares of health insurers are trading higher following a WSJ report indicating the Trump administration will increase Medicare Advantage rates.

HUM: 16% &#x7C; <a href="https://www.benzinga.com//node/44674240">Shares of health insurers are trading higher following a WSJ report indicating the Trump administration will increase payment rates for Medicare insurers.</a>
&nbsp;
MRVL: 7% &#x7C; <a href="https://www.benzinga.com//node/44680589">Marvell Technology shares are trading higher after Infineon Technologies agreed to acquire its Automotive Ethernet Business for $2.5 billion in cash.</a>
&nbsp;
NYXH: 62% &#x7C; <a href="https://www.benzinga.com//node/44678177">Nyxoah Nears FDA Approval For Genio System Following Approvable Letter Confirming PMA Requirements Are Substantially Met</a>

NYXH

Market-Moving News for April 8th

Health insurer stocks are trading higher after the market close on Monday following a report indicating the Trump administration will increase payment rates <a href="https://www.benzinga.com/topic/medicare">for Medicare insurers</a>.
What Happened: The Centers for Medicare and Medicaid Services (CMS) announced Monday that it will increase payment rates for Medicare insurers to 5.06%. The rate is well above the 2.23% proposed by the Biden administration and above all prior analyst expectations, according to the <a href="https://www.wsj.com/health/healthcare/private-medicare-plans-to-get-big-payment-boost-from-trump-administration-017d9aaa">Wall Street Journal</a>.
The report indicates that investors are expected to view the increase as a show of support from the Trump administration for Medicare Advantage, under which private companies can offer Medicare-approved insurance plans. 
&#8220;By finalizing these payment policies, CMS is ensuring that Medicare Advantage continues to offer access to critical services in an efficient, accountable manner, further strengthening the program's ability to serve beneficiaries,&#8221; the Medicare agency <a href="https://www.cms.gov/newsroom/press-releases/cms-finalizes-2026-payment-policy-updates-medicare-advantage-and-part-d-programs">said</a> in a press release.
The new head of CMS Mehmet Oz has long been a supporter of private insurance plans in Medicare, according to the Wall Street Journal. CMS reportedly said the payment rate increase reflects higher medical costs. 
&#8220;The actions taken by CMS help protect beneficiaries and taxpayers from waste, fraud, and abuse, while also driving access to high-quality, affordable healthcare through Medicare Advantage,&#8221; CMS said.
Here&#8217;s a look at some of the health insurer stocks making big moves following the announcement:
<ul>
<li>CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) up 6.50% at $68</li>
</ul>
<ul>
<li>UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) up 5.77% at $555</li>
</ul>
<ul>
<li>Humana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) up 12.08% at $285.49</li>
</ul>
<ul>
<li>Elevance Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) up 6.35% at $450</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44669062/top-3-health-care-stocks-that-may-crash-in-q2">Top 3 Health Care Stocks That May Crash In Q2</a></li>
</ul>
Photo: Shutterstock.

After-Hours Center

Health Insurers Surge After Medicare Agency Increases Payment Rates

Press Releases

AM Best Assigns Issue Credit Ratings to Humana Inc.'s New Senior Unsecured Notes

Humana Completes Aggregate $1.25 Billion Debt Offering

CenterWell, Icon Health Collaborate to Transform Musculoskeletal Care for Seniors

CenterWell Bringing Convenient, Personalized Health Care to Seniors at Gladstone Walmart

AM Best Comments on Humana Inc.'s Re-Opened Senior Unsecured Notes

Legal

HUMANA ALERT: Bragar Eagel & Squire, P.C. is Investigating Humana Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Humana Inc. Announces Dates for First Quarter 2025 Earnings and June Investor Conference

Humana's Initiatives Deliver Improved Health Outcomes in Communities

New Report from the Humana Foundation Examines Best-Practices in Community-Engaged Research

Comments

Humana

Intérêt court

Humana (NYSE:HUM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL